Quantcast

Industry news that matters to you.  Learn more

Roche Receives FDA Approval for VENTANA ALK (D5F3) CDx Assay to Identify Lung Cancer Patients Eligible for Treatment with Roche’s ALECENSA (alectinib)

Roche recently announced it has obtained US Food and Drug Administration (FDA) approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Roche medicine ALECENSA® (alectinib). The VENTANA ALK (D5F3) CDx Assay is the only test FDA-approved as a companion diagnostic for ALECENSA.

Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

Biodesix presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the AACR-NCI-EORTC conference. The study was conducted in collaboration with Dr. Michael Pritchett, from FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, and Dr. Jiaxin Niu, from Banner MD Anderson Cancer Center.

New Study: Videssa Breast Blood Test Can Effectively Rule Out Breast Cancer, Regardless of Breast Density

A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer by Provista Diagnostics, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.

Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass

Tyme Technologies, Inc. (Nasdaq: TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced it has identified a mechanism and related biomarker that the Company believes could potentiate the calcification of tumors. During clinical evaluation of the Company’s lead product candidate, it was observed that subsequent to SM-88 therapy some lytic bone lesions converted to benign sclerotic bone. Following further examination, the Company believes it has isolated the cause of this conversion and developed a treatment method that can be used in combination with SM-88 to cause calcification of tumors with a particular biomarker. The Company has conducted a small number of tests in canine osteosarcoma and observed positive results, including a rapid ossification of tumors.

Singapore Scientists Develop New DNA Technology to Detect Breast Cancer Relapse

Researchers in Singapore, together with international collaborators from Denmark and USA, have successfully identified a unique biomarker that is strongly associated with breast cancer relapse. This finding has led to the development of a simple blood test which has numerous clinical applications, such as detecting relapse early and testing treatment efficacy. The study was recently published in scientific journal Nature Medicine in September 2017.